Pharmacy

Your Article Summary

See Latest Articles

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

The US Food and Drug Administration has approved Valturna tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system, an important regulator of blood pressure. This is the first approval for Valturna, which is indicated for the treatment of high blood pressure in patients not adequately controlled on aliskiren or angiotensin receptor blocker monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

Today in Cardiac/Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia
Resuscitation, 11/18/09

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
Pediatric Cardiology, 11/18/09

The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk
Annals of Pharmacotherapy, 11/18/09

 See all of Cardiac/Hypertension

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09

Human genome sciences receives complete response letter from fda for raxibacumab biologics license application
Human Genome Sciences, 11/17/09

Panenza, Sanofi Pasteurs Influenza A(H1N1) 2009 Vaccine, Approved in France
Sanofi-aventis, 11/17/09

 See all of Drug Approvals